Back to top Open menu arrow
Reprints

The Journal of
Clinical Psychiatry
Free access

Insights February 17, 2022

Emerging Treatments in Schizophrenia Video

; ;

Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.

Read the InfoPack

About the Authors

Figure. Journal cover highlights articles on bipolar II depression therapy, schizophrenia treatment, and adult ADHD symptoms.

Vol 86 • 2025 • Number 4

Read the Current Issue

Original Research

Effects of Interpersonal and Social Rhythm Therapy on Suicidal Ideation in Adults with Bipolar II Depression

Academic Highlights

Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report

Academic Highlights

Psychosocial Interventions and Functional Recovery in Schizophrenia

Original Research

Symptom Network Analysis of ADHD and Emotional Symptoms in Adults

Original Research

Emory Treatment Resistance Interview for PTSD—Short Version

Original Research

Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder
View current Issue

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe